PDF Cover

Single Port Surgical Robots Market

Single Port Surgical Robots Market

The market for Single Port Surgical Robots was estimated at $2.6 billion in 2024; it is anticipated to increase to $6.7 billion by 2030, with projections indicating growth to around $14.6 billion by 2035.

Report ID:DS1801593
Author:Debadatta Patel - Senior Consultant
Published Date:September 2025
Datatree
Life Science
Medical Device
Single Port Surgical Robots
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Single Port Surgical Robots Market Outlook

Revenue, 2024

$2.6B

Forecast, 2034

$12.5B

CAGR, 2024 - 2034

16.8%
The Single Port Surgical Robots industry revenue is expected to be around $3.1 billion in 2025 and expected to showcase growth with 16.8% CAGR between 2025 and 2034. The initial success of single port surgical robotics has evolved into a strategic foundation for providers who want to establish minimally invasive procedures and improve operating room efficiency. The market demand stems from patient needs for minimal scarring and quick recovery along with surgeon comfort and hospital requirements to reduce patient stay duration and maintain consistent quality standards. The growing clinical evidence base combined with reimbursement opportunities and comprehensive training systems enable sustained utilization of the technology across tertiary and ambulatory centers which drives service line expansion and competitive advantage.

Single port surgical robots perform complex procedures by using a single incision at the umbilicus to execute multi articulating instruments and 3D visualization which creates triangulation within limited anatomical spaces. The system features wristed tools and tremor filtration and advanced energy integration and fluorescence imaging to improve both precision and workflow. The technology finds its main use in urology and gynecology and general and colorectal surgical procedures.

Single Port Surgical Robots market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Single Port Surgical Robots market is projected to grow from $2.6 billion in 2024 to $12.5 billion in 2034. This represents a CAGR of 16.8%, reflecting rising demand across Urologic Radical Prostatectomy, Transoral Robotic Surgery (TORS) for Oropharyngeal Lesions and Renal Partial Nephrectomy.
  • The market exhibits an oligopolistic structure with only 6 prominent players, with Intuitive Surgical and Vicarious Surgical commanding the largest shares.
  • U.S. and China are the top markets within the Single Port Surgical Robots market and are expected to observe the growth CAGR of 16.1% to 23.5% between 2024 and 2030.
  • Emerging markets including India, Brazil and Mexico are expected to observe highest growth with CAGR ranging between 12.6% to 17.5%.
  • Transition like Single Entry Precision Becomes the Standard is expected to add $1.5 billion to the Single Port Surgical Robots market growth by 2030
  • The Single Port Surgical Robots market is set to add $9.9 billion between 2024 and 2034, with manufacturer targeting General Surgery & Gynecology Applications projected to gain a larger market share.
  • With Preference for single-incision robotic procedures, and Enhanced surgical precision with reduced scarring., Single Port Surgical Robots market to expand 373% between 2024 and 2034.
single port surgical robots market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Single Port Surgical Robots

US payers and CMS are moving hysterectomy, prostatectomy, and cholecystectomy to ASCs, focusing on shorter stays and lower total cost of care. Compact single port surgical robots with AI enhanced visualization, wristed instruments, and rapid turnover suit small OR footprints and high throughput. The fastest growth will be in single port urologic and gynecologic systems designed for outpatient workflows, reusable instruments, and ASC chain partnerships.

Growth Opportunities in North America and Asia Pacific

North America Outlook

The single port surgical robot market in North America continues to thrive because of its dense tertiary care networks and reimbursement for minimally invasive surgery and strong procedure volumes in urology, colorectal, and transoral head and neck oncology. The competitive market for surgical robots is led by Intuitive Surgicals da Vinci SP while Medtronics IP position and academic spin outs indicate potential new entrants that could challenge pricing and service models. The market will expand through FDA approved new indications and integrated imaging systems and AI enabled workflow solutions and hospital value analyses that focus on total cost of ownership and utilization and training pathways to enhance surgeon proficiency and speed up deployment.

Asia Pacific Outlook

The Asia Pacific region presents growth opportunities because of its developing surgical infrastructure and public funding and increasing robotic assisted surgery adoption in China, South Korea, Japan, India and ASEAN medical tourism hubs. The domestic OEMs maintain their position in the market through single incision platform development and they use local manufacturing and distributor networks and tender based procurement to reduce lifecycle costs. The regulatory momentum from Koreas approvals and Chinas support for domestic surgical robotics together with training center investments will expand new specialties and boost case numbers but hospitals will select modular upgrades and flexible solutions and evidence based ROI because of price sensitivity and capital constraints.

Market Dynamics and Supply Chain

01

Driver: Rising demand for scarless, rapid recovery care and hospital shift to ambulatory MIS driving Single Port Surgical Robots

Hospitals now focus on marketing single incision robotic assisted surgery because patients increasingly want scarless procedures with minimal pain recovery. Single Port Surgical Robots provide better cosmesis and less postoperative pain and faster return to work than multiport laparoscopy because of patient preference for scarless and minimal pain recovery. The combination of provider economic factors and payer pressure also drives the transition to outpatient ambulatory surgery centers and day case pathways which focus on short hospital stays and minimal operating room requirements; single port platforms decrease the number of ports and staff interactions and reduce operating room turnover time which supports value based care. The urologic procedures of radical prostatectomy and partial nephrectomy will also experience the greatest growth because of their strong clinical evidence and ASC suitability and concentrated urology robotics expertise.
The combination of wristed flexible instruments with an articulating endoscope and stable 3D visualization in next generation single port architectures enhances both reach and triangulation capabilities in tight spaces including the oropharynx and deep pelvis. The technology provides better instrument alignment and precise suturing capabilities while reducing setup time compared to multiport systems. The technology will also benefit most from transoral head and neck surgery because it enables better access to the base of tongue and supraglottic larynx and hypopharynx which expands patient candidacy and reduces morbidity and increases surgeon adoption of Single Port Surgical Robots.
02

Restraint: High Capital Costs and Total Cost of Ownership

Single Port Surgical Robots require high upfront capital expenditure, ongoing service contracts, expensive instruments, and staff training, stretching hospital budgets and delaying procurement decisions, especially in community hospitals and emerging markets where cost benefit analysis favors multiport systems with broader case versatility. Tender evaluations and value based care metrics penalize platforms with higher per procedure costs and uncertain ROI, dampening demand and lowering utilization rates; for example, urology and gynecology departments may consolidate cases on existing multiport robots to avoid duplicative spend, slowing new installations and elongating replacement cycles.
03

Opportunity: GCC private hospitals scaling bariatric surgery for medical tourism, catalyzing Single Port Surgical Robots and Tier two Chinese hospitals expanding colorectal and hepatobiliary oncology, accelerating Single Port Surgical Robots

The growing obesity rates in Saudi Arabia, UAE, and Kuwait drive increased interest in minimally invasive bariatric procedures and luxury medical tourism packages. Private hospital groups are investing in single port robots that minimize scarring, pain, and length of stay while enabling high throughput sleeve gastrectomy. The market will experience its greatest expansion through single port bariatric configurations and stapling capable instruments which will be supported by vendor financed deals and proctoring programs and regional centers of excellence marketing initiatives.
The increasing oncology burden in China drives medical procedures toward tier two cities where hospitals adopt minimally invasive techniques to decrease hospital stay duration and minimize infection risks. The combination of domestic single port platforms with volume based procurement and DRG reimbursement creates favorable economic conditions. The provincial networks will experience the most significant growth through cost optimized single port colorectal and hepatobiliary robots because of service ecosystems and flexible disposable pricing and training collaborations with academic centers.
04

Challenge: Clinical, Operational, and Reimbursement Barriers

The steep learning curve and extended initial operative time and restricted indications and workflow integration problems prevent surgeons from adopting the technology which leads administrators to delay purchases until training programs and standardized protocols become established. The absence of separate reimbursement for single incision procedures combined with inconsistent regulatory approvals diminishes both revenue growth and clinical trust which drives demand toward flagship centers while peripheral hospitals stay away from platform risk because of unclear payer coverage and conversion rate uncertainty that results in selective case choices and reduced procedure numbers and delayed market entry.

Supply Chain Landscape

1
Components & Subsystems

Harmonic Drive

Maxon

OmniVision

2
OEM Manufacturing

Intuitive Surgical

Medrobotics

Virtual Incision

3
Channels & Procurement

Vizient

Premier

HealthTrust

4
End Users

Academic Medical Centers

Tertiary Hospitals

Ambulatory Surgery Centers

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Single Port Surgical Robots in Urologic Radical Prostatectomy, Transoral Robotic Surgery (TORS) for Oropharyngeal Lesions & Renal Partial Nephrectomy

Urologic Radical Prostatectomy

The Intuitive da Vinci SP platform serves as the primary tool for single port robotic prostatectomy because it enables three wristed instruments and a 3D endoscope to pass through one cannula for both transperitoneal and extraperitoneal access. The procedure provides surgeons with better cosmetic outcomes and decreased postoperative discomfort and better access to pelvic region's through narrow spaces while preserving oncologic precision and nerve sparing capabilities. The market leader Intuitive Surgical maintains broad FDA approvals and extensive customer base and training initiatives while Titan Medical emerges as a potential competitor for single port urology systems.

Transoral Robotic Surgery (TORS) for Oropharyngeal Lesions

The da Vinci SP system serves as the primary tool for single port TORS procedures to remove oropharyngeal tumors through a mouth gag without requiring external incisions. The procedure provides better visualization of small spaces and reduces tracheostomies while shortening hospital stays and accelerating swallowing recovery. The market for TORS remains dominated by Intuitive through its dedicated instruments and strong KOL advocacy while startups Titan Medical and academic consortia test single port concepts although commercial adoption continues under Intuitive leadership.

Renal Partial Nephrectomy

The da Vinci SP enables single port renal surgery through one umbilical or flank incision for retroperitoneal or transperitoneal access which allows precise tumor excision and renorrhaphy under warm ischemia control with internal triangulation. The procedure provides patients with reduced wound complications and better aesthetic results and better ergonomic suturing capabilities in confined retroperitoneal region's. The market leadership of Intuitive Surgical exists due to its established clinical workflows and service support while Titan Medicals ENOS platform exists in development stage as a potential future competitor after receiving clinical validation and regulatory approvals.

Recent Developments

October 2024

The company Vicarious Surgical announced its plans to shut down operations and sell its assets which led to the termination of its single port surgical robot development program and demonstrated the consolidation trends in the category.

March 2024

Virtual Incision obtained FDA De Novo clearance for its MIRA Surgical System to perform adult colectomy thus starting U. S. commercialization of its miniaturized single incision robotic platform.

May 2023

Titan Medical signed an asset purchase and license agreement with Intuitive Surgical to transfer key single port robotics intellectual property which consolidated patents under a leading provider and reshaped competitive dynamics.

Single port surgical robots gained momentum because of new single port platforms that received US/EU clearances and improved articulation and slimmer cannulas and AI guided visualization while OEM partnerships with imaging, energy, and instrument suppliers accelerated ecosystem integration. Strategic investments and tuck in acquisitions consolidated IP and manufacturing scale, strengthening pricing power and hospital procurement reach.

Impact of Industry Transitions on the Single Port Surgical Robots Market

As a core segment of the Medical Device industry, the Single Port Surgical Robots market develops in line with broader industry shifts. Over recent years, transitions such as Single Entry Precision Becomes the Standard and Outpatient Adoption Reshapes Economics have redefined priorities across the Medical Device sector, influencing how the Single Port Surgical Robots market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Single Entry Precision Becomes the Standard

Single Port Surgical Robots enable minimally invasive surgery through single entry precision which enhances cosmesis and reduces trauma and shortens hospital stays without compromising instrument articulation or 3D visualization. Operating rooms undergo redesign to implement new workflows and training programs for wristed instruments and flexible endoscopes which optimize single port triangulation procedures to reduce both turnover times and supply waste. The adoption of single port prostatectomy and hysterectomy procedures by urology and gynecology lines leads to faster patient discharge and reduced analgesic requirements which accelerates recovery times and increases market demand for compatible imaging and stapling and simulation products throughout the medtech supply chain. This industry transition is expected to add $1.5 billion in the industry revenue between 2024 and 2030.
02

Outpatient Adoption Reshapes Economics

The combination of single port robotic assisted surgery with its reduced anesthesia requirements and lower complication rates leads to procedures being performed in ambulatory surgery centers which supports value based care and cost efficiency goals. The transition to robot as a service models and disposable instrument ecosystems and digital OR integration with AI driven imaging enhances both utilization rates and predictable per case economics. Single port platforms in ASC based cholecystectomy programs increase daily outpatient procedure capacity which reduces episode costs for payers while forcing medtech distributors and sterilization partners and cybersecurity providers to modify their logistics and contracts and remote proctoring systems.

Related Reports

Loading related reports...